Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Marina Kremyanskaya

Marina Kremyanskaya

Icahn School of Medicine at Mount Sinai
Early findings from the Phase I/II SANRECO study: divesiran in polycythemia vera 4:08
Early findings from the Phase I/II SANRECO study: divesiran in polycythemia vera
Marina Kremyanskaya • 17 Jun 2025
Combination strategies under investigation in myelofibrosis and their use in the frontline setting 1:57
Combination strategies under investigation in myelofibrosis and their use in the frontline setting
Marina Kremyanskaya • 17 Jun 2025
The evolution of treatment options for myelofibrosis: newly available JAK inhibitors and beyond 2:31
The evolution of treatment options for myelofibrosis: newly available JAK inhibitors and beyond
Marina Kremyanskaya • 17 Jun 2025
The evolving treatment landscape for patients with polycythemia vera 3:37
The evolving treatment landscape for patients with polycythemia vera
Marina Kremyanskaya • 9 Dec 2024
Initial results of the SANRECO trial evaluating divesiran in patients with polycythemia vera 1:57
Initial results of the SANRECO trial evaluating divesiran in patients with polycythemia vera
Marina Kremyanskaya • 9 Dec 2024
LBA: results of REVIVE – rusfertide in patients with polycythemia vera 5:40
LBA: results of REVIVE – rusfertide in patients with polycythemia vera
Marina Kremyanskaya • 10 Jun 2023
Updated results from MANIFEST arm 2: pelabresib as add-on to ruxolitinib in myelofibrosis 3:43
Updated results from MANIFEST arm 2: pelabresib as add-on to ruxolitinib in myelofibrosis
Marina Kremyanskaya • 10 Jun 2023
The impact of symptoms on QoL in patients with MPNs 1:32
The impact of symptoms on QoL in patients with MPNs
Marina Kremyanskaya • 10 Jun 2023
An update on REVIVE: rusfertide in patients with polycythemia vera 5:42
An update on REVIVE: rusfertide in patients with polycythemia vera
Marina Kremyanskaya • 17 May 2022
Managing splenomegaly in patients with myelofibrosis 3:44
Managing splenomegaly in patients with myelofibrosis
Marina Kremyanskaya • 17 May 2022
Ongoing clinical trials of ruxolitinib-based combinations in myelofibrosis 5:12
Ongoing clinical trials of ruxolitinib-based combinations in myelofibrosis
Marina Kremyanskaya • 17 May 2022
Management strategies for advanced systemic mastocytosis 4:46
Management strategies for advanced systemic mastocytosis
Marina Kremyanskaya • 17 May 2022
MANIFEST: ruxolitinib plus pelabresib for JAK-inhibitor naïve myelofibrosis 3:21
MANIFEST: ruxolitinib plus pelabresib for JAK-inhibitor naïve myelofibrosis
Marina Kremyanskaya • 15 Jun 2021
Rusfertide reduces need for therapeutic phlebotomy in PV patients 5:56
Rusfertide reduces need for therapeutic phlebotomy in PV patients
Marina Kremyanskaya • 15 Jun 2021
The content of VJHemOnc is intended for healthcare professionals